HCPLive

GOLD discusses some COPD biologics but leaves them out of its algorithm. How should clinicians read that evidence?

Dave Singh, MD, explains, plus what changed in the 2027 GOLD report. #copd

hcplive.com/conference/gol…

New from #AHA2026: We spoke with Luke Laffin, MD, from Cleveland Clinic, regarding the Transform-HTN open-label extension and lorundrostat's role in inhibiting aldosterone to reduce uncontrolled hypertension.

Watch now: hubs.li/Q04DYpd80

A new drug gets approved. Can your patient get it, and will insurance require step therapy first?

Autumn Burnette, MD, of @HowardU tackles those questions on Allergy Rounds with Dr. Autumn, a new #allergy & immunology HCPLive podcast:

hcplive.com/podcasts/aller…

New at #AHA2026: We spoke with Michelle O'Donoghue, MD, to discuss the results of Part A of the TYDAL-TIMI 78 trial investigating MAR001 in reducing fasting triglyceride in patients with elevated levels and remnant cholesterol.

Watch now: hubs.li/Q04DYsFj0

Up to 5 years of lebrikizumab. 3 years of nemolizumab. 2 years of icotrokinra.
October's long-term dermatology data, plus the rest of the month's headlines you may have missed:
hubs.li/Q04DXYtv0